Mumps is a highly contagious human disease, characterized by lateral or bilateral nonsuppurative swelling of the parotid glands and neurological complications that can result in aseptic meningitis or encephalitis. A mumps vaccination program implemented since the 1960s reduced mumps incidence by more than 99% and kept the mumps case numbers as low as hundreds of cases per year in the United States before 2006. However, a large mumps outbreak occurred in vaccinated populations in 2006 and again in 2009 in the United States, raising concerns about the efficacy of the vaccination program. Previously, we have shown that clinical isolate-based recombinant mumps viruses lacking expression of either the V protein (rMuVΔV) or the SH protein (rMuVΔSH) are attenuated in a neurovirulence test using newborn rat brains (P. Xu et al., Virology 417:126–136, 2011, dx.doi.org/10.1016/j.virol.2011.05.003; P. Xu et al., J. Virol. 86:1768–1776, 2012, dx.doi.org/10.1128/JVI.06019-11) and may be good candidates for vaccine development. In this study, we examined immunity induced by rMuVΔSH and rMuVΔV in mice. Furthermore, we generated recombinant mumps viruses lacking expression of both the V protein and the SH protein (rMuVΔSHΔV). Analysis of rMuVΔSHΔV indicated that it was stable in tissue culture cell lines. Importantly, rMuVΔSHΔV was immunogenic in mice, indicating that it is a promising candidate for mumps vaccine development.

In this study, we tested the immunogenicity of rMuVΔSH and rMuVΔV in mice. Furthermore, we generated a recombinant mumps virus lacking expression of both the SH and V proteins (rMuVΔSHΔV) and examined antibody and cellular immune responses in mice.

**MATERIALS AND METHODS**

**Plasmids, viruses, and cells.** The MuV strain was obtained from a patient during the 2005–2006 Midwest mumps outbreak in the United States. A full-length cDNA clone of the virus (pMuV) was constructed as previously described (21). Recombinant MuV lacking the V protein (rMuVΔV), recombinant MuV lacking the SH protein, and recombinant MuV lacking both the V and SH proteins (rMuVΔSHΔV) were used in this study.

In this study, we seek to develop a mumps vaccine candidate through genetic modification of a clinically isolated mumps virus. Mumps virus is a member of the family *Paramyxoviridae*, subfamily *Paramyxovirinae*, and genus *Rubulavirus* (6, 14). It is an enveloped virus enclosing a negative-sense, single-stranded, nonsegmented RNA genome of 15,384 nucleotides in length which encodes 9 viral proteins (15–17). Studies of the function of the *Paramyxovirus* SH protein reveal that it blocks tumor necrosis factor alpha (TNF-α) induction, signaling, caspase activation, and NF-kB nuclear translocation in transfected and virus-infected cells (18–23). The V protein is an accessory protein translated from the authentic transcript of the V/P gene (24, 25). Mumps V protein is an antagonist of antiviral innate immunity. It interferes with type I interferon (IFN) induction by disrupting the recognition of intracellular viral double-stranded RNA (dsRNA) by MDA5 (26–28). It also blocks IFN signaling by targeting STAT proteins for proteasome-mediated degradation (29–35). Recombinant mumps viruses with either the V protein deletion (rMuVΔV) or the SH protein deletion (rMuVΔSH) are attenuated in neurotoxicity in intracerebrally (IC) infected rats (21, 36). In this study, we tested the immunogenicity of rMuVΔV and rMuVΔSH in mice. Furthermore, we generated a recombinant MuV lacking expression of both the SH and V proteins (rMuVΔSHΔV) and examined antibody and cellular immune responses in mice.
MuV expressing a Renilla luciferase protein have been described before (21). A plasmid containing the MuV genome but lacking both V and SH was constructed by combining the SH open reading frame (ORF) deletion with the plasmid encoding the rMuVΔV genome. Primer sequences, detailed cloning strategies, and entire cDNA sequences of MuV are available upon request. Jeryl Lynn (IL) vaccine, isolated from the measles, mumps, and rubella (MMR) vaccine, was a gift from Paul Rota at the CDC.

To rescue an infectious virus, plasmid pMuVΔASHΔV (5 μg), along with plasmids pCAGGS-L (1 μg), pCAGGS-NP (1.5 μg), and pCAGGS-P (200 ng), were transfected into BSRT-7 cells. Three days later, transfected BSRT-7 cells were mixed with Vero cells at a 1:1 ratio. Ten to 14 days later, when syncytium formation was observed, supernatants containing putative rMuVΔASHΔV were collected and plaque purified in Vero cells. Plaques (developing 4 to 7 days postinfection [dpi]) were amplified in Vero cells once (P1), and their genomes were sequenced. All recombinant viruses used for the following experiments were expanded once in Vero cells from the P1 amplification (P2). The rescue procedure was repeated to produce independent stocks of rMuVΔASHΔV, resulting in 6 isolates of independently rescued rMuVΔASHΔV viruses (PX64-1, PX64-4, PX64-61, PX64-67, and PX64-84).

All mumps viruses were grown in Vero cells and harvested at 4 to 7 dpi. Virus titers were measured in Vero cells by plaque assay as described previously (37, 38). JL virus was grown in Vero cells and concentrated to achieve 80 to 90% confluence the next day. For virus infection, cells were treated with 3 ml of Gey’s solution (ammonium chloride, 8.29 g/liter; potassium bicarbonate, 1 g/liter) for 5 min at room temperature (RT) to lyse red blood cells. The residual supernatant were washed once with 50 ml Hanks’ balanced salt solution (HBSS) per spleen and resuspended in 10 ml complete tumor medium (CTM) containing 0.75 g/liter d-glucose (Sigma), 7.5 ml/liter essential amino acids (50X) (Invitrogen), 14 ml/liter sodium bicarbonate (Sigma), 1% gentamicin-penicillin G-streptomycin (Sigma) were washed after incubation, blotted with biotinylated anti-mouse antibody (MAb R4-6A2; MABTECH) and streptavidin-alkaline phosphatase (Sigma-Aldrich) followed by the Institutional Animal Care and Use Committee of the University of Georgia.

The ELISPOT assay. Splenocytes were isolated from mouse spleens at the time of euthanasia. Spleens were ground, filtered through cell strainers (BD Falcon), and washed once with 50 ml of Hanks’ balanced salt solution (Life Technologies) per spleen. Washed splenocytes from each spleen were treated with 3 ml of Gey’s solution (ammonium chloride, 8.29 g/liter; potassium bicarbonate, 1 g/liter) for 5 min at room temperature (RT) to lyse red blood cells. The residual splenocytes were washed once with 50 ml Hanks balanced salt solution (HBSS) per spleen and resuspended in 10 ml complete tumor medium (CTM) containing 0.75 g/liter d-glucose (Sigma), 7.5 ml/liter essential amino acids (50X) (Invitrogen), 14 ml/liter nonessential amino acids (100X) (Invitrogen), 10 ml/liter sodium pyruvate (100X) ( Gibco), 10 ml/liter l-glutamine (100X) ( Gibco), 0.85 g/liter sodium bicarbonate (Sigma), 1% gentamicin-penicillin G streptomycin sulfate (Sigma), and 3.4 μl/liter 2-mercaptoethanol (Fisher) in minimum essential medium, Spinner modification (S-MEM; Sigma). Splenocytes were counted and reconstituted to a concentration of 3 x 10^5 cells/ml and 1.5 x 10^5 cells/ml in CTM. One hundred μl of splenocytes was plated onto prepared enzyme-linked immunosorbent spot (ELISPOT) plates (MultiScreen-IP without underdrain; 0.45 μm, white, sterile; Millipore). The ELISPOT plates were precoated with anti-mouse IFN-γ (AN-18; MAABTECH) overnight, washed with sterile PBS five times, and incubated with CTM for 1 h at RT. One hundred μl of CTM containing either mock-infected or MuV-infected Vero cell lysates at 50 μg/ml was overlaid onto splenocytes as a stimulant. Vero cell lysates were prepared by rounds of sonication and several freeze-thaw cycles to activate any infectious viral particles. The mixture of splenocytes and viral antigens was incubated for 40 to 48 h at 37°C with 5% CO₂. The plates were washed after incubation, blotted with biotinylated anti-mouse IFN-γ antibody (Ab R4+6A2; MAABTECH) and streptavidin-alkaline phosphatase (MAABTECH), and developed in 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium (KPL).

ELISA. Enzyme-linked immunosorbent assay (ELISA) was performed as previously described (40). Briefly, immunol 2 HB 96-well microtiter plates (ThermoLab Systems) were coated with MuV proteins at 2 μg/ml and incubated at 4°C overnight. Plates were then washed with KPL wash oxidase (1:1,000) (KPL, Inc.) and detected using an Amersham ECL Western blotting detection kit (GE Healthcare Bioscience, Piscataway, NJ).

Multicycle growth curve in Vero cells. Vero cells in 6-well plates or 6-well plates were mock infected or infected with rMuV, JL, rMuVΔV, rMuVΔSH, or rMuVΔASHΔV (multiple isolates) at an MOI of 0.01. One ml (6-well plate) or 100 μl (6-well plate) of supernatant was collected at 1, 2, 3, 4, and 5 dpi, supplemented with 1% BSA, and stored at –80°C. Virus titers were determined by plaque assay in triplicate using Vero cells in 6-well plates. After 1 to 2 h of incubation with the viruses, the growth medium was changed to DMEM with 2% FBS, 1% P/S, and 1% low-melting-point agarose. Four to 7 dpi, the Vero cells were stained with Giemsa stain and plaques were counted.

Immunization of mice. BALB/c mice (female, 6 to 8 weeks old) were purchased from Charles River Laboratories (Frederick, MD). Mice were immunized with 1 x 10^6 PFU of rMuV, JL, rMuVΔV, rMuVΔSH, or rMuVΔASHΔV in a volume of 100 μl for intranasal (i.n.) vaccination. For intramuscular (i.m.) vaccination, mice were injected with 25 μl of inoculum into each side of the caudal thigh bilaterally (10^6 PFU). i.n.- or i.m.-vaccinated mice were boosted with the same amount of virus inoculum as the primary vaccination on the 21st or 22nd day after primary vaccination. Blood samples were obtained from mock or recombinant MuV-vaccinated mice through tail vein puncture. At the termination of each experiment, mice were euthanized with 500 ml of Avertin (2,2,2-tribromoethanol) (Sigma-Aldrich) followed by cervical dislocation. Splenocytes were removed from the mice for splenocyte isolation and in vitro analysis. All mouse immunizations and studies with mumps viruses were performed in enhanced biosafety level 2 facilities with HEPA-filtered isolators and were conducted by following protocols reviewed and approved by the Institutional Animal Care and Use Committee of the University of Georgia.
cross-reactivity of JL and MuV. BALB/c mice were i.n. or i.m. immunized with PBS, MuV, or JL at 10^6 PFU/mouse and boosted at 22 days post-vaccination with the same virus at 10^6 PFU/mouse. Serum samples were collected at 14 days postboost. Heat-inactivated serum samples of individual mice from the same group were pooled to perform the plaque reduction neutralization test (PRNT). Serum samples were 2-fold serial diluted from 1:30 to 1:3,840. A volume of 120 μl diluted serum was mixed with 120 μl diluted virus containing 80 PFU of either JL or rMuV virus and incubated at 37°C for 1 h. The count of residual unneutralized PFU per 100 μl was determined by plaque assay in 6-well plates of Vero cells. PRNT titer is determined as the first dilution level with residual PFU of more than half of the input per 100 μl.

solution (KPL, Inc.), and each well was blocked with 200 μl KPL wash solution with 5% nonfat dry milk and 0.5% BSA (Blotto) for 1 h at RT. Serum samples were inactivated by heating at 56°C for 0.5 h and were serially diluted 2-fold or 4-fold in Blotto. One hundred μl of diluted serum samples was transferred to the coated plate and incubated for 1 h at RT. To detect anti-MuV specific antibodies, alkaline phosphatase (AP)-labeled, goat anti-mouse IgG (KPL, Inc.) was diluted in Blotto according to the manufacturer’s instructions, added to each well, and incubated for 1 h at RT. Plates were washed and developed by adding 100 μl pnPP phosphatase substrate (KPL, Inc.) per well. Optical density (OD) was measured at 405 nm on a Bio-Tek Powerwave XS plate reader.

Luciferase activity-based neutralization assay. Serum samples were serially diluted 2-fold starting from 1:10 or 1:40 up to 1:20,480. Recombinant virus expressing a Renilla luciferase protein (rMuV-Luc) was diluted to 2,000 PFU/ml in 1% BSA-DMEM. One portion of serum (40 μl) was mixed with an equal volume of rMuV-Luc virus (80 PFU/40 μl) into each well of a 96-well plate and incubated at 37°C with 5% CO2. Each 96-well plate contained five serum samples and one standard in duplicate. After 1 h of incubation, trypsinized Vero cells in 4% FBS, 2% P/S in DMEM were added to each well of the 96-well plates. At 48 to 72 h postinfection, infected Vero cells were lysed and analyzed for total luciferase activity per well using the Renilla Luciferase assay system (Promega) and a Veritas microplate luminometer (Promega). The neutralizing titer was calculated as the highest dilution level with luciferase readings exceeding that produced by 40 PFU of rMuV-Luc virus in standard control wells.

Statistics. P values were calculated using Student’s t test (two-tailed, type 2). Correlations of titers determined by luciferase activity-based neutralization assay to that determined by plaque reduction neutralization assay were calculated by R^2.

RESULTS

Immunogenicity of recombinant mumps viruses lacking either the V protein or the SH protein in mice. To analyze the immunogenicity of the current mumps vaccine, JL, and the clinical MuV isolate from the 2006 outbreak (referred to as MuVv), mice were vaccinated with JL or MuV via the intranasal (i.n.) or intramuscular (i.m.) route and boosted at 22 days postprimary vaccination with the same virus, dose, and route as the primary vaccination. Serum samples were collected at 14 days postboost (dpb). As expected, JL generated higher neutralizing antibody titers against JL than MuV, and MuV generated higher anti-MuV titers than JL, regardless of the route of immunization (Fig. 1). This result is consistent with a previous report that sera from JL-vaccinated humans had higher anti-JL neutralizing titers than anti-MuV neutralizing titers (41).

Previous studies have shown that rMuVΔV (lacking V protein expression) or rMuVΔSH (lacking SH protein expression) are attenuated in a neurovirulency potency test in rat brains (21, 36), suggesting these viruses are good candidates for vaccine development. To investigate the immunogenicity and vaccine potential of rMuVΔV and rMuVΔSH in mice, BALB/c mice were mock vaccinated (PBS) or vaccinated with rMuV, JL, rMuVΔSH, or rMuVΔV and boosted at 22 days postprimary vaccination through i.m. injection with the same virus and dose as the primary vaccination. We chose the i.m. route because the trivalent MMR vaccine is usually administered by intramuscular (i.m.) or deep subcutaneous injection (42), but mostly via i.m. administration. Serum samples were collected at 14 dpb. The total IgG antibody titer against MuVv was measured by ELISA using plates coated with purified MuV (Fig. 2). We found that all groups generated robust anti-MuV antibody responses.

Mumps virus is a human respiratory virus transmitted via respiratory secretions such as saliva and nose and throat discharge (6), i.n. vaccination induces both local immunity in the respiratory tract and systemic immunity. Mucosal immunity provides direct and rapid protection against virus challenge. To examine the immunogenicity of rMuVΔV and rMuVΔSH compared to that of rMuVv and JL, BALB/c mice were mock vaccinated (PBS) or vaccinated with rMuV, JL, rMuVΔSH, or rMuVΔV intranasally and boosted at 22 days postprimary vaccination with the same virus type and dose as the primary i.n. vaccination. Serum samples were collected at 14 dpb. Total IgG antibody titers against MuVv were measured by ELISA (Fig. 3). All groups generated robust anti-MuVv antibody responses.

Rescue of recombinant viruses lacking both V and SH proteins. To further enhance the safety of vaccine candidates, we constructed a recombinant mumps virus lacking expression of both the V and SH proteins. The genome length of the newly synthesized cDNA (pMuVΔSHΔV) complied with the rule of six for Paramyxovirus...
Infectious recombinant viruses (rMuV\(\Delta SH\Delta V\)) were rescued from BSRT-7 cells transfected with pMuV\(\Delta SH\Delta V\) and helper plasmids as described before (21). To confirm rescue of the virus, viral RNA was extracted from cell culture medium containing rescued viruses (Fig. 4B). The SH gene and the V/P gene region were amplified using reverse transcription-PCR and sequenced. As shown in Fig. 4, the SH ORF truncation as well as the V deletion was confirmed (Fig. 4C and D).

To confirm that genomic changes in rMuV\(\Delta SH\Delta V\) abolish V and SH expression, Vero cells were mock infected or infected with rMuV or rescued rMuV\(\Delta SH\Delta V\) (PX64-67 strain). Expression levels of MuV NP, P, V, and SH proteins were examined using Western blotting. While NP and P were detected in both rMuV- and rMuV\(\Delta SH\Delta V\)-infected cells, expression of V or SH protein was only detected in rMuV-infected Vero cells (Fig. 4E).

FIG 3 i.n. immunization with rMuV\(\Delta SH\) or rMuV\(\Delta V\) induced antibody responses in mice. BALB/c mice were i.n. vaccinated with PBS, rMuV, JL, rMuV\(\Delta SH\), and rMuV\(\Delta V\) with \(10^6\) PFU and boosted 22 days postvaccination with \(10^6\) PFU. Serum samples were collected at 14 dpb, and total antibody titers of these samples were measured by ELISA coated with MuV viral proteins.

FIG 4 Generation of recombinant MuV lacking V and SH proteins (rMuV\(\Delta SH\Delta V\)). (A) Schematics of pMuV\(\Delta SH\Delta V\). A 156-bp section was removed from the SH gene of pMuV\(\Delta V\), a cDNA genome of mumps virus lacking expression of V protein. (B) Reverse transcription-PCR confirmed the mutation in the SH ORF in rescued rMuV\(\Delta SH\Delta V\). Recombinant viruses (rMuV\(\Delta SH\Delta V\)) were rescued from pMuV\(\Delta SH\Delta V\) through transfection of BSRT-7 cells with pMuV\(\Delta SH\Delta V\), together with the helper plasmids (pCAGGS-L, pCAGGS-NP, and pCAGGS-P). RNA was extracted from rMuV\(\Delta SH\Delta V\)-infected Vero cells. Two primers, PX47F and PX48R (sequences are available upon request), were used to amplify the SH gene region. (C and D) Sequence confirmation of the mutated regions in the SH ORF and the V/P editing site. The reverse transcription-PCR product of the SH gene was sent for sequencing. Sequencing results confirmed the mutation was successfully introduced into rMuV\(\Delta SH\Delta V\). (E) Western blot confirmation of the deletion of V and SH proteins in rMuV\(\Delta SH\Delta V\) viruses. Vero cells were mock infected or infected with rMuV or rMuV\(\Delta SH\Delta V\) at an MOI of 0.5. Cell lysates were collected at 48 hpi and were blotted against MuV NP, P, V, and SH proteins.

March 2014 Volume 88 Number 5 jvi.asm.org

Novel Mumps Vaccine

(43). Infectious recombinant viruses (rMuV\(\Delta SH\Delta V\)) were rescued from BSRT-7 cells transfected with pMuV\(\Delta SH\Delta V\) and helper plasmids as described before (21). To confirm rescue of the virus, viral RNA was extracted from cell culture medium containing rescued viruses (Fig. 4B). The SH gene and the V/P gene region were amplified using reverse transcription-PCR and sequenced. As shown in Fig. 4, the SH ORF truncation as well as the V deletion was confirmed (Fig. 4C and D).

To confirm that genomic changes in rMuV\(\Delta SH\Delta V\) abolish V and SH expression, Vero cells were mock infected or infected with rMuV or rescued rMuV\(\Delta SH\Delta V\) (PX64-67 strain). Expression levels of MuV NP, P, V, and SH proteins were examined using Western blotting. While NP and P were detected in both rMuV- and rMuV\(\Delta SH\Delta V\)-infected cells, expression of V or SH protein was only detected in rMuV-infected Vero cells (Fig. 4E).

Analysis of rMuV\(\Delta SH\Delta V\) in tissue culture cells. To select an rMuV\(\Delta SH\Delta V\) virus that replicates well for vaccine production purposes, the replication capability of rMuV\(\Delta SH\Delta V\) viruses from 6 in-
the former strains (Fig. 5A). PX64-67 had a growth pattern similar to rMuV, had titers ranging from 5.5 PFU/ml, and the other three strains (PX64-1, PX64-2, and PX64-81) reached the peak virus titer within the first 72 h postinfection (hpi), PX64-4 grew slower than the others and peaked at 96 hpi. Three strains (PX64-67) were compared by multicycle plaque assay, from which virus titer was calculated. (B) Multicycle growth kinetics of rMuV and parental viruses (shVV and rMuV) in Vero cells with previously published data (21), rMuV and rMuV viruses were about a half log lower in virus titer. The virus titer of rMuV decreased after 48 hpi, remaining about a half log lower than that of rMuV and one log lower than that of rMuV or rMuV (Fig. 5B).

Intracellular viral protein expression of rMuV was compared to that of rMuV. NP, P, and V protein expression levels were examined (Fig. 5C). Comparable NP and P protein levels were detected in Vero cells infected with rMuV or rMuV. However, secretion of infectious viral particles of rMuV-infected Vero cells was less than that of rMuV-infected Vero cells at all time points postinfection (Fig. 5C). At 48 hpi, a more intense P protein band was observed in rMuV-infected cells than in rMuV-infected cells, consistent with a previous report of higher P expression at early time points in rMuV viruses, a likely result of increased P transcription from the V/P gene due to deletion of the V mRNA transcript (36). Expression of the V protein was only detected in rMuV-infected cells.

Maintenance of V and SH protein deletion in rMuV through 10 passages in Vero cells. To examine the stability of rMuV, it was passaged in Vero cells continuously for 10 passages at a low MOI. At passage 10 (rMuV SH P10), the culture medium from infected Vero cells was used for viral RNA extraction, followed by whole-genome sequencing to determine the consensus genome sequence. Sequencing results revealed 3 additional mutations: 1 silent mutation in the HN ORF, an R154K mutation in P, and an N2063H mutation in L. Interestingly, the G-A nucleotide mutation at position 2445 in the P ORF is the first nucleotide of the 6-guanine editing site (GGGGGG) of the V/P gene, which has been altered to GAGGAGGG in rMuV and rMuV viruses (36). Importantly, none of these mutations affected deletion of V or SH.

Furthermore, 10 single plaques (designated SP-1 to SP-10) were obtained from rMuV SH P10, and the V/P and SH gene regions were sequenced (Table 1). The V protein and the SH ORF deletion were maintained in all 10 progeny strains from passage 10, including the 1913 C-T mutation in the NP gene end region. While 9 out of 10 strains contained the 2445 G-A mutation in the V/P gene editing site, 1 strain lost/failed to retain this mutation. To confirm that the 2445 G-A mutation had no effect on the V protein deletion, expression of the V protein in SP-1 to SP-10-infected Vero cells was examined by Western blotting (Fig. 6). No expression of V was detected, indicating that the mutation had no effect on V protein deletion.

Intramuscular immunization of BALB/c mice with rMuV SH generated an antibody response against MuV. BALB/c mice were i.m. vaccinated with rMuV, JL, rMuV SH, rMuV, or the highest virus titer among rMuV SH viruses. Therefore, it was chosen and designated rMuV SH for the following studies. Previously, when we obtained rMuV SH mutations in regions other than the designed V/P editing site always arose. The entire genome of the rescued rMuV SH viruses were sequenced to determine whether genome-wide mutations occurred during virus rescue. PX64-67 contained an additional single-nucleotide change (C-T) in genomic position 1913 (termed 1913 C-T) (NP gene end) and 7894 T-A silent (HN ORF) mutations compared to rMuV. To compare the growth of rMuV SH to rMuV and parental viruses (shVV and rMuV), Vero cells were infected with rMuV, rMuV SH, rMuV, and rMuV SH at an MOI of 0.01. While rMuV SH showed growth kinetics comparable to those of rMuV, consistent...
**TABLE 1** V/P gene and SH gene sequences of rMuVΔSHΔV P10 single plaque-purified viruses

<table>
<thead>
<tr>
<th>Virus</th>
<th>V protein deletion</th>
<th>NP GE or V/P GS mutation</th>
<th>V/P editing site mutation</th>
<th>SH ORF deletion</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP-1</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>2445 G-A</td>
<td>Yes</td>
</tr>
<tr>
<td>SP-2</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>2445 G-A</td>
<td>Yes</td>
</tr>
<tr>
<td>SP-3</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>2445 G-A</td>
<td>Yes</td>
</tr>
<tr>
<td>SP-4</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>2445 G-A</td>
<td>Yes</td>
</tr>
<tr>
<td>SP-5</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>1578 A-C</td>
<td>Yes</td>
</tr>
<tr>
<td>SP-6</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>2445 G-A</td>
<td>Yes</td>
</tr>
<tr>
<td>SP-7</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>2445 G-A</td>
<td>Yes</td>
</tr>
<tr>
<td>SP-8</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>2445 G-A</td>
<td>Yes</td>
</tr>
<tr>
<td>SP-9</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>2445 G-A</td>
<td>Yes</td>
</tr>
<tr>
<td>SP-10</td>
<td>Yes</td>
<td>1913 C-T</td>
<td>2445 G-A</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*For V/P and SH gene regions of SP-1 to SP-10 were sequenced. The V/P and SH gene regions of SP-1 to SP-10 were sequenced. Mutations found in these regions are shown.*

rMuVΔSHΔV as described above. Serum samples were collected as described previously. Serum IgG antibody titers against MuV were measured using ELISA with plates coated with MuV viral proteins (lysed virions). Neutralizing antibody titers against MuV were measured by an rMuV-Luc-based neutralization assay as described in Materials and Methods (linear correlation of rMuV-Luc-based neutralization assay to traditional plaque reduction neutralization assay was confirmed by an $R^2$ value of 0.9317 using ferret serum samples [data not shown]). Similar approaches have been used for adenovirus, measles virus, and respiratory syncytial virus (RSV) to substitute for the traditional plaque reduction neutralization test (PRNT) (44–47). We used rMuV-Luc, which was constructed based on the genetic background of MuV, as the targeting virus to compare the potentials of humoral responses induced by the vaccine candidates as well as the JL strain in mice to protect against the circulating mumps virus in the United States. No significant differences were detected among the groups for total antibody titers (Fig. 7A). However, the neutralizing antibody titers of serum samples showed some differences. The average neutralizing titer of JL-inoculated mice was significantly lower than that of rMuV-infected mice, which had the highest neutralizing titer. Mice inoculated with rMuVΔSH, rMuVΔV, or rMuVΔSHΔV had similar average titers (Fig. 7B).

Intranasal immunization of BALB/c mice with rMuVΔSHΔV generated an antibody response against MuV. BALB/c mice were i.n. inoculated with rMuV, JL, rMuVΔSH, rMuVΔV, or rMuVΔSHΔV at 10⁶ PFU, and serum samples were collected for measurement of both total antibody titer and neutralizing titer against MuV. rMuVΔSH-inoculated mice developed the highest total antibody titer, and the rMuV group had a higher titer than the JL group. No significant differences were detected among the JL group, rMuVΔV group, and rMuVΔSHΔV groups (Fig. 8A). The rMuV group had the highest neutralizing titer, the JL group had the lowest neutralizing titer, and the other three groups (rMuVΔSH, rMuVΔV, and rMuVΔSHΔV) ranked between them (Fig. 8B). Although i.n.-immunized mice exhibited neutralizing antibody titer patterns like those observed in the i.m. groups, statistically significant differences were found between the rMuV and JL groups ($P = 0.001$), JL and rMuVΔSH groups ($P = 0.001$), JL and rMuVΔSHΔV groups ($P = 0.038$), and rMuVΔV and rMuVΔSH groups ($P = 0.034$).

Adaptive T cell responses were induced in mice vaccinated with rMuVΔSHΔV. To investigate the cellular immune responses induced by rMuVΔSHΔV, i.m.- or i.n.-inoculated mice were euthanized at 28 dpb and splenocytes were isolated for ELISPOT assay. In i.m.-inoculated mice, the JL group had the highest T cell response levels and rMuVΔSHΔV had the lowest T cell response levels, with no distinguishable differences among the rMuV, rMuVΔSH, and rMuVΔV groups (Fig. 9A). Differences were significant between JL and rMuVΔSH, JL and rMuVΔSHΔV, rMuVΔSH and rMuVΔSHΔV, and rMuVΔV and rMuVΔSHΔV. In i.n.-inoculated mouse groups, rMuV- and rMuVΔV-immu-
nized mice had the lowest responding cell counts (Fig. 9B). Significant differences were observed between JL and rMuVΔSHΔV, rMuV and rMuVΔSH, rMuV and rMuVΔSHΔV, rMuVΔSH and rMuVΔV, and rMuVΔV and rMuVΔSHΔV groups.

**DISCUSSION**

The JL vaccine is one of the most successful vaccines developed during the third quarter of the last century. It was produced by the propagation of mumps virus in embryonated hen’s eggs that resulted in attenuation (48–51). Introduction of the *in vitro* tissue/cell culture technique into vaccinology facilitated the development and production of the majority of currently licensed live-attenuated vaccines in the United States against viral infections (52–56). For mumps vaccine candidates, JL is the great success, but unfortunately there were many failures. Different passages of attenuated viruses were tested in animal models or in field trials in order to select a vaccine seed with the most reduced virulence and greatest immunogenicity (1). Selected vaccine candidates need to be biologically characterized in order to be distinguished from virulent strains. There are currently no standardized attenuation markers for mumps vaccines, partially due to the semirational and semiempirical nature of the traditional attenuation method (1, 57–60). The rate of aseptic meningitis following vaccination with JL (estimated one case per 1.8 million doses) is below background levels (61). However, other live attenuated mumps virus vaccines have had much higher incidences of vaccine-associated meningitis. The Urabe vaccine, which was widely distributed in Japan, Europe, and Canada, is estimated to cause one case of meningitis in every 1,000 to 11,000 doses distributed in the United Kingdom and one case of meningitis in every 62,000 doses distributed in Canada. The Urabe vaccine has been withdrawn due to safety concerns.

In this study, based on the establishment of reverse genetic technology of negative-sensed, nonsegmented RNA viruses...
V virus rescue (36). This mutation is believed to be important for the V/P GS region, which has been previously seen in the course of virus passages in the HN and L ORFs, rMuV Vi s

regaining of the V protein or the SH protein was observed in any virus during virus growth. 

emphasizing the significance of a proper ratio between NP and P protein during virus growth.

One challenge of developing a new mumps vaccine is the lack of correlation between protection and immune responses. While a neutralization titer is thought to be essential in protection against mumps infection (79), investigations of serum samples of patients versus nonpatients during recent mumps outbreaks revealed no defined cutoff neutralizing antibody titer against mumps virus, indicating a potential role for cellular immunity in effective protection against mumps challenge (41, 86). In this study, the investigation of immunogenicity of rMuVΔSHΔV in i.n.- and i.m.-vaccinated mice showed that rMuVΔSHΔV was able to induce a neutralizing titer comparable to those induced by rMuVΔSH and rMuVΔV and a higher titer than that induced by JL vaccine. Furthermore, rMuVΔSHΔV vaccination also stimulated T cell responses in mice, although the role of cell-mediated immunity in mumps disease protection remains to be demonstrated. We also observed that rMuVΔSH induced slightly higher total antibody titers than those induced by rMuV, and rMuVΔSHΔV induced higher antibody titers than those induced by rMuVΔV, suggesting that deletion of SH leads to better antigen presentation. Similar results have been reported for a closely related virus, paramyxovirus virus 5 (PIV5), in which PIV5 lacking SH is more immunogenic than PIV5 (88). The mouse models have been widely used to test vaccine efficacy for various human viruses (89–92). However, it is not a good model for mumps virus infection. The efficacy of rMuVΔSHΔV in nonhuman primates, which is a good model for mumps virus infection (40), should be examined before testing this candidate in humans. In summary, rMuVΔSHΔV was able to elicit both antibody and cellular responses against MuV in i.n.- and i.m.-vaccinated mice, providing a safe and immunogenic mumps vaccine candidate.

ACKNOWLEDGMENTS

We appreciate the comments, suggestions, and technical help from members of the He laboratory. We thank Paul Rota for providing the JL vaccine strain. We are grateful to Kaori Sakamoto for carefully reading the manuscript prior to submission.

This work has been supported by a grant from the NIH (AI097368 to B.H.).

REFERENCES


Fuentes S, Crim RL, Beeler J, Teng MN, Golding H, Khurana S. 2013. Development of a simple, rapid, sensitive, high-throughput luciferase re-


59. Kaptsova TI, Alekseeva AK, Gordienko NM, Rozina EE, Ermakova MN. 1976. Results of a study of live mumps vaccine from strain L-3 produced in chick embryos. Biken J.


